Biological and clinical characteristics of patients with CN AML in the German AML series (GSE12417)
| . | CN-AML series . |
|---|---|
| Patients, n | 223 |
| Males/females, n | N.A. |
| Median follow-up, y | 8.84 |
| Age group, n | |
| 0-14 y | 0 |
| 15-39 y | 46 |
| 40-59 y | 79 |
| ≥60 y | 98 |
| Median presenting leukocyte count, ×109/L | N.A. |
| ELN cytogenetic risk group, n | |
| Favorable | 0 |
| Intermediate | 223 |
| Adverse | 0 |
| N.A. | 0 |
| PI group, n | |
| Low (≤1.0) | 63 |
| Intermediate (1.0 < PI < 1.5) | 92 |
| High (≥1.5) | 68 |
| Gene-expression platform | Affymetrix Human Genome U133 Plus 2.0, U133A/B Array |
| . | CN-AML series . |
|---|---|
| Patients, n | 223 |
| Males/females, n | N.A. |
| Median follow-up, y | 8.84 |
| Age group, n | |
| 0-14 y | 0 |
| 15-39 y | 46 |
| 40-59 y | 79 |
| ≥60 y | 98 |
| Median presenting leukocyte count, ×109/L | N.A. |
| ELN cytogenetic risk group, n | |
| Favorable | 0 |
| Intermediate | 223 |
| Adverse | 0 |
| N.A. | 0 |
| PI group, n | |
| Low (≤1.0) | 63 |
| Intermediate (1.0 < PI < 1.5) | 92 |
| High (≥1.5) | 68 |
| Gene-expression platform | Affymetrix Human Genome U133 Plus 2.0, U133A/B Array |